Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin

Yuk Fung Hui, Jorge E. Cortes

Research output: Contribution to journalArticle

Abstract

Daunorubicin and doxorubicin are anthracyclines that have efficacy against malignancies such as breast cancer, lung cancer, lymphoma, and leukemia. Their adverse effects are similar. The most serious is cardiotoxicity, which often limits the total cumulative dose that can be administered. Introduction of a liposomal formulation for both agents allows tumor selectivity by accumulating the drug in tumor tissue, thus increasing the tolerated dose. Liposomal doxorubicin is commonly associated with palmar-plantar erythrodysesthesia syndrome (PPES), although no reports of PPES were found in the literature related to liposomal daunorubicin (L-DNR). Two patients developed PPES while receiving high-dose L-DNR. The symptoms were self-limiting and resolved within a few weeks.

Original languageEnglish (US)
Pages (from-to)1221-1223
Number of pages3
JournalPharmacotherapy
Volume20
Issue number10
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Daunorubicin
Lung Neoplasms
Neoplasms
Anthracyclines
Doxorubicin
Lymphoma
Leukemia
Breast Neoplasms
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin. / Hui, Yuk Fung; Cortes, Jorge E.

In: Pharmacotherapy, Vol. 20, No. 10, 01.01.2000, p. 1221-1223.

Research output: Contribution to journalArticle

@article{53c4ca5c3bb84f2ea4257cc27420f120,
title = "Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin",
abstract = "Daunorubicin and doxorubicin are anthracyclines that have efficacy against malignancies such as breast cancer, lung cancer, lymphoma, and leukemia. Their adverse effects are similar. The most serious is cardiotoxicity, which often limits the total cumulative dose that can be administered. Introduction of a liposomal formulation for both agents allows tumor selectivity by accumulating the drug in tumor tissue, thus increasing the tolerated dose. Liposomal doxorubicin is commonly associated with palmar-plantar erythrodysesthesia syndrome (PPES), although no reports of PPES were found in the literature related to liposomal daunorubicin (L-DNR). Two patients developed PPES while receiving high-dose L-DNR. The symptoms were self-limiting and resolved within a few weeks.",
author = "Hui, {Yuk Fung} and Cortes, {Jorge E.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1592/phco.20.15.1221.34593",
language = "English (US)",
volume = "20",
pages = "1221--1223",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin

AU - Hui, Yuk Fung

AU - Cortes, Jorge E.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Daunorubicin and doxorubicin are anthracyclines that have efficacy against malignancies such as breast cancer, lung cancer, lymphoma, and leukemia. Their adverse effects are similar. The most serious is cardiotoxicity, which often limits the total cumulative dose that can be administered. Introduction of a liposomal formulation for both agents allows tumor selectivity by accumulating the drug in tumor tissue, thus increasing the tolerated dose. Liposomal doxorubicin is commonly associated with palmar-plantar erythrodysesthesia syndrome (PPES), although no reports of PPES were found in the literature related to liposomal daunorubicin (L-DNR). Two patients developed PPES while receiving high-dose L-DNR. The symptoms were self-limiting and resolved within a few weeks.

AB - Daunorubicin and doxorubicin are anthracyclines that have efficacy against malignancies such as breast cancer, lung cancer, lymphoma, and leukemia. Their adverse effects are similar. The most serious is cardiotoxicity, which often limits the total cumulative dose that can be administered. Introduction of a liposomal formulation for both agents allows tumor selectivity by accumulating the drug in tumor tissue, thus increasing the tolerated dose. Liposomal doxorubicin is commonly associated with palmar-plantar erythrodysesthesia syndrome (PPES), although no reports of PPES were found in the literature related to liposomal daunorubicin (L-DNR). Two patients developed PPES while receiving high-dose L-DNR. The symptoms were self-limiting and resolved within a few weeks.

UR - http://www.scopus.com/inward/record.url?scp=0033770416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033770416&partnerID=8YFLogxK

U2 - 10.1592/phco.20.15.1221.34593

DO - 10.1592/phco.20.15.1221.34593

M3 - Article

C2 - 11034047

AN - SCOPUS:0033770416

VL - 20

SP - 1221

EP - 1223

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 10

ER -